Inflammatory bowel disease-related arthritis – clinical evaluation and possible role of cytokines

Objectives In inflammatory bowel disease (IBD), characterized by chronic mucosal inflammation, rheumatic abnormalities ranging from arthralgia to spondyloarthritis (SpA) are the most common extraintestinal manifestations. The pathogenesis of IBD-related arthritis is unclear. In this study, we search for clinical and immunological differences between patients with IBD-associated spondyloarthritis and IBD patients without SpA symptoms. Material and methods Patients with an established diagnosis of IBD, suffering from Leśniowski-Crohn disease (L-CD, n = 24) or ulcerative colitis (UC, n = 27), were enrolled in the study. Clinical evaluation of patients, based on medical history, blood tests, physical and radiological examinations, allowed two subgroups of patients to be established. One subgroup comprised patients fulfilling criteria for both IBD and SpA (IBD + SpA, n = 29), while the other included IBD patients with arthralgia only (IBD, n = 22). Serum concentrations of interleukins (IL-6, IL-10, IL-21, IL-22, IL-23) and interferon γ (IFN-γ) were measured by specific enzyme-linked immunosorbent assays (ELISA). Results Patients with IBD + SpA were characterized by shorter disease duration (3 vs. 9 years), higher frequency of HLA-B27 positivity (60.7% vs. 4.5%) and uveitis (20.7% vs. 0%), compared with the IBD subgroup. The serum concentrations of C-reactive protein (CRP) and tested cytokines did not differ between IBD + SpA and IBD patients, or between L-CD and UC groups. However, in the IBD + SpA subgroup there was weak to moderate positive correlation between serum concentrations of CRP and several cytokines (IL-6, IL-21, IFN-γ), and additional moderate positive correlation between serum concentrations of IL-23 and clinical activity of SpA. By contrast, in IBD subgroup a strong inverse correlation between serum concentrations of Interleukin 23 and CRP was found. Conclusions IBD-related spondyloarthritis occurs relatively early, affects mostly HLA-B27(+) individuals, and is often accompanied by ocular involvement. In these patients several circulating cytokines are associated with systemic inflammation. IL-23 seems to be protective in IBD while detrimental in IBD-related spondyloarthritis.

[1]  M. Brzosko,et al.  Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome , 2015, Mediators of inflammation.

[2]  S. Pellom,et al.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn’s Colitides , 2015, Clinical medicine insights. Gastroenterology.

[3]  B. Nowak,et al.  Cytokine profiles in axial spondyloarthritis , 2015, Reumatologia.

[4]  A. Deodhar,et al.  Treatment of spondyloarthritis beyond TNF-alpha blockade. , 2014, Best practice & research. Clinical rheumatology.

[5]  M F Neurath,et al.  New targets for mucosal healing and therapy in inflammatory bowel diseases , 2013, Mucosal Immunology.

[6]  P. Sarzi-Puttini,et al.  Rheumatic manifestations in inflammatory bowel disease. , 2014, Autoimmunity reviews.

[7]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[8]  Chang-Youh Tsai,et al.  Association of serum interleukin‐17 and interleukin‐23 levels with disease activity in Chinese patients with ankylosing spondylitis , 2012, Journal of the Chinese Medical Association : JCMA.

[9]  S. Snapper,et al.  Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance , 2012, Journal of Gastroenterology.

[10]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general , 2010, Annals of the rheumatic diseases.

[11]  R. Misra,et al.  Th-17 associated cytokines in patients with reactive arthritis/undifferentiated spondyloarthropathy , 2011, Clinical Rheumatology.

[12]  K. Stengaard-Pedersen,et al.  Increased Interleukin 21 (IL-21) and IL-23 Are Associated with Increased Disease Activity and with Radiographic Status in Patients with Early Rheumatoid Arthritis , 2010, The Journal of Rheumatology.

[13]  F. Pallone,et al.  Interleukin-21 triggers effector cell responses in the gut. , 2010, World journal of gastroenterology.

[14]  Judy H. Cho,et al.  Interleukin-23/Th17 pathways and inflammatory bowel disease. , 2009, Inflammatory bowel diseases.

[15]  W. Fries,et al.  Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. , 2009, World journal of gastroenterology.

[16]  I. Monteleone,et al.  Interleukin-23 and Th17 Cells in the Control of Gut Inflammation , 2009, Mediators of inflammation.

[17]  F. Powrie,et al.  The interleukin‐23 axis in intestinal inflammation , 2008, Immunological reviews.

[18]  S. Targan,et al.  Recent advances in IBD pathogenesis: Genetics and immunobiology , 2008, Current gastroenterology reports.

[19]  M. Neurath,et al.  Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. , 2006, Journal of immunology.

[20]  D. Baeten,et al.  Gut inflammation in the spondyloarthropathies , 2005, Current rheumatology reports.

[21]  D. Hommes,et al.  Interleukin-10-based therapy for inflammatory bowel disease , 2003, Expert opinion on biological therapy.

[22]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[23]  M. Vos,et al.  Gut inflammation and spondyloarthropathies , 2002, Current rheumatology reports.

[24]  I. Olivieri,et al.  Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. , 2001, Scandinavian journal of gastroenterology.

[25]  C. G. González Fernández,et al.  Clinical significance of abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondyloarthropathies , 2000, European Journal of Nuclear Medicine.

[26]  T. Toyota,et al.  Enhanced interferon-gamma production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. , 1995, Journal of gastroenterology.

[27]  M. Leirisalo-Repo,et al.  High frequency of silent inflammatory bowel disease in spondylarthropathy. , 1994, Arthritis and rheumatism.

[28]  J A Walker-Smith,et al.  Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. , 1993, Immunology.

[29]  E. Bywaters Reumatologia , 1972 .